BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22987298)

  • 1. Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and sesamin treatment.
    Akl MR; Ayoub NM; Sylvester PW
    Planta Med; 2012 Nov; 78(16):1731-9. PubMed ID: 22987298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines.
    Akl MR; Ayoub NM; Abuasal BS; Kaddoumi A; Sylvester PW
    Fitoterapia; 2013 Jan; 84():347-59. PubMed ID: 23266736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1.
    Wali VB; Bachawal SV; Sylvester PW
    Exp Biol Med (Maywood); 2009 Jun; 234(6):639-50. PubMed ID: 19359655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
    Bachawal SV; Wali VB; Sylvester PW
    BMC Cancer; 2010 Mar; 10():84. PubMed ID: 20211018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic anticancer effects of combined γ-tocotrienol and oridonin treatment is associated with the induction of autophagy.
    Tiwari RV; Parajuli P; Sylvester PW
    Mol Cell Biochem; 2015 Oct; 408(1-2):123-37. PubMed ID: 26112904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
    Samant GV; Sylvester PW
    Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
    Bachawal SV; Wali VB; Sylvester PW
    Anticancer Res; 2010 Feb; 30(2):429-37. PubMed ID: 20332450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells.
    Hsieh TC; Wu JM
    Int J Oncol; 2008 Oct; 33(4):851-9. PubMed ID: 18813800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells.
    Wali VB; Sylvester PW
    Lipids; 2007 Dec; 42(12):1113-23. PubMed ID: 17701065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
    Sylvester PW; Shah S
    Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity.
    Shah SJ; Sylvester PW
    Exp Biol Med (Maywood); 2005 Apr; 230(4):235-41. PubMed ID: 15792944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis.
    Parajuli P; Tiwari RV; Sylvester PW
    Biol Pharm Bull; 2015; 38(9):1352-60. PubMed ID: 26328490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.
    Ayoub NM; Bachawal SV; Sylvester PW
    Cell Prolif; 2011 Dec; 44(6):516-26. PubMed ID: 21973114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells.
    Parajuli P; Tiwari RV; Sylvester PW
    Cell Prolif; 2015 Aug; 48(4):421-35. PubMed ID: 26096843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
    Shirode AB; Sylvester PW
    Biomed Pharmacother; 2010 May; 64(5):327-32. PubMed ID: 19954924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of gamma-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells.
    Liu HK; Wang Q; Li Y; Sun WG; Liu JR; Yang YM; Xu WL; Sun XR; Chen BQ
    J Nutr Biochem; 2010 Mar; 21(3):206-13. PubMed ID: 19195866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular signaling mechanisms mediating the antiproliferative and apoptotic effects of gamma-tocotrienol in neoplastic mammary epithelial cells.
    Sylvester PW; Shah SJ; Samant GV
    J Plant Physiol; 2005 Jul; 162(7):803-10. PubMed ID: 16008108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells.
    Alawin OA; Ahmed RA; Ibrahim BA; Briski KP; Sylvester PW
    J Nutr Biochem; 2016 Jan; 27():266-77. PubMed ID: 26507543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.
    Ayoub NM; Akl MR; Sylvester PW
    Cell Prolif; 2013 Oct; 46(5):538-53. PubMed ID: 24033536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy.
    Sylvester PW; Ayoub NM
    Anticancer Agents Med Chem; 2013 Sep; 13(7):1039-47. PubMed ID: 23272909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.